TNFRSF14 and lymphoma: Overall, treatment with tifcemalimab/icatolimab was well-tolerated and demonstrated preliminary clinical efficacy in solid tumors and lymphomas, thus encouraging further investigation of BTLA/HVEM axis as a promising target for immunotherapy.